Rani Therapeutics, LLC, a clinical-stage biotherapeutics company focused on oral delivery of biologics and drugs, has expanded its footprint in Silicon Valley with a new lease for 33,340 square feet of manufacturing, R&D and administrative space in Fremont. The company’s subsidiary has signed the lease at Bayside Commons technology park owned by BKM Capital Partners.
The strategic location along the I-880 Corridor offers convenience to Rani’s existing facilities in North San Jose and Milpitas. Cushman & Wakefield represented Rani in this expansion deal.
According to Alex Lagemann from Cushman & Wakefield,”This market expansion showcases Silicon Valley as a key global hub for biotech/life sciences companies.” With this move,Rani is nearly doubling its space from approximately 34,000 square feet.
